Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity
- 1 October 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in European Journal of Gastroenterology & Hepatology
- Vol. 22 (10), 1235-1238
- https://doi.org/10.1097/meg.0b013e32833aa11b
Abstract
Isoniazid, rifampicin, and pyrazinamide, the first-line antituberculosis (anti-TB) drugs, are associated with hepatotoxicity.To study the hepatoprotective effect of N-acetylcysteine (NAC) on liver injury induced by anti-TB drugs.A randomized clinical trial was conducted on 60 new TB patients who were aged 60 years or more. Patients were randomized into two groups. In group I (n=32), drug regimen included daily doses of isoniazid, rifampicin, pyrazinamide, and ethambutol. Patients in group II (n=28) were treated with the same regimen and NAC. The patients were followed up for 2 weeks. Liver enzymes and bilirubins were measured at baseline, after 1 and 2 weeks of treatment, and whenever the patients presented with clinical symptoms of hepatotoxicity.The mean+/-SD values of aspartate aminotransferase and alanine aminotransferase were significantly higher in group I than in group II after 1 and 2 weeks of treatment. Hepatotoxicity occurred in 12 patients with (37.5%) group I and none in group II. The mean duration of treatment before the onset of hepatotoxicity was 4.67+/-4.58 days.NAC protects against anti-TB drug-induced hepatotoxicity.Keywords
This publication has 12 references indexed in Scilit:
- Incidence, Clinical and Epidemiological Risk Factors, and Outcome of Drug-Induced Hepatitis Due to Antituberculous Agents in New Tuberculosis CasesClinical Journal of Sport Medicine, 2010
- An Official ATS Statement: Hepatotoxicity of Antituberculosis TherapyAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Role of N-acetylcysteine in rifampicin-induced hepatic injury of young ratsWorld Journal of Gastroenterology, 2006
- Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberclosis treatmentPharmacological Research, 2005
- Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individualsEuropean Journal of Clinical Pharmacology, 2004
- Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitisHepatology, 2003
- Evaluation of Clinical and Immunogenetic Risk Factors for the Development of Hepatotoxicity during Antituberculosis TreatmentAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Isoniazid – and rifampicin–induced oxidative hepatic injury – protection by N–acetylcysteineHuman & Experimental Toxicology, 2000
- Study of Oxidative-Stress in Isoniazid-Rifampicin Induced Hepatic Injury in Young RatsDrug and Chemical Toxicology, 1997
- Toxic Hepatitis with Isoniazid and RifampinChest, 1991